Old products that have past primary, secondary and tertiary rollouts. Me too products fighting for shelf space without enough strategic clinical differentiation or a significant value proposition to be of value if sold off. BV, where the whole is less than the sum of its parts. Once upon a time, before JA, and the spin-off, this was a decent business unit. BUT, never a stand alone company. I hope everyone finds a new happy home.
